3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
2
Phase 1/2
2
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
2
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Graft vs Host Disease
1
Interventions
Dexamethasone
11
Lenalidomide
10
Bortezomib
9
Zoledronic Acid
8
ixazomib
4
daratumumab
4
Melphalan
4
tocilizumab
3
Thalidomide
3
Cyclophosphamide
3
pomalidomide
2
carfilzomib
2
Prednisone
2
Kyphoplasty
2
Filgrastim
2
Doxorubicin
2
Calcium Dobesilate
2
zanubrutinib
1
talquetamab
1
pegylated granulocyte colony-stimulating factor
1
montelukast
1
isatuximab
1
ibrutinib
1
exifone
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
apixaban
1
Vaccination
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Multiple Myeloma
×
ibrutinib
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled